S100A9 and Alzheimer disease: Given that the accumulation of S100A8 aggregates precedes Aβ plaque formation in murine models of AD [55], exploiting its protective function or targeted prevention of S100A8 accumulation or its interaction with Aβ or its other targets may be a viable therapeutic strategy, as demonstrated for S100A9 in ref. [49,50].